Journey Medical (Nasdaq: DERM) missed on both lines in the third quarter. The Earnings Whispers data lists the ticker under the Dermira name, but the release and call are Journey Medical's. The company lost $0.05 per share against a consensus of a $0.03 loss, a 66.7% shortfall. Revenue of $18.97 million came in 7.7% below the $20.54 million estimate. On a year-over-year basis the picture is better: earnings improved 44.4% as the net loss narrowed from $0.09 per share, and revenue grew 7.6%. Those comparisons hide the real problem. Growth is decelerating sharply just as investors were looking for Emrosi to inflect. Total revenue growth fell to 8% from 23% in the second quarter and 21% in the first.

The quality of the earnings miss is better than the headline suggests. The quality of the revenue miss is not. A one-time $1.7 million vendor dispute settlement ran through SG&A, and that charge alone exceeded the entire $1.3 million GAAP net loss. Gross margin improved to 69% from 67%. Adjusted EBITDA reached $3.5 million, up from $2.9 million in Q2 and $0.6 million in Q1. EBITDA has now been positive for a second straight quarter. Revenue is the harder issue, and no one-off explains it. Emrosi delivered $9.0 million, up 84% year over year and up from $8.1 million in Q2. That means the rest of the nine-brand portfolio contributed only about $10 million, so the legacy business shrank from a year ago. Other revenue also fell to $42 thousand from $606 thousand. Total revenue rose only about $0.5 million sequentially.

The call explained where Emrosi's momentum leaked. Total prescriptions reached roughly 40,000, but sequential growth slowed to about 8% from roughly 20% in Q2. Management raised the copay bridge from $35 to $50 to improve gross-to-net, and that change produced volatility in late September and October. Third-party data showed October prescriptions running below the Q3 weekly average, a plausible fourth-quarter headwind. High-quality commercial coverage edged up only to about 40% from 38%. The underlying engagement metrics were still healthy:

• Unique prescribers topped 5,000, versus 4,500 in Q2, hitting the full-year goal early.
• Refills rose about 12% sequentially.
• Average selling price has risen every quarter this year.

The brand is getting more valuable per script, but volume growth is cooling.

The most meaningful forward catalyst is payer access. Management said the largest U.S. national health plan, covering more than 25 million lives, is expected to add Emrosi to its formulary in January 2027. That follows another large national plan addition in early August, and management expects more national and regional wins in early 2027. Q1 deductible resets could delay the benefit, so the payoff may lag the headline. Management also highlighted several other initiatives:

• A post-hoc Phase III analysis showing about 30% of patients reached clear skin versus 12.8% on Oracea.
• A possible further sales force expansion.
• A second switching-trial program in 2027.

The credibility cost of the quarter is significant. Detailed financial guidance promised on the Q1 call for later this year has been deferred, and management sounded hesitant about guiding even in the first half of 2027. The "breakout year" framing from earlier calls was gone.

The balance sheet adds to the caution. Cash slipped to $22.3 million from $25.6 million at the end of Q2 and $27.2 million at the end of Q1. Accounts receivable climbed to $47.4 million from $29.8 million at year-end. Meanwhile, $7.5 million of the term loan has moved into current liabilities. The company's own risk factors continue to cite substantial doubt about its ability to continue as a going concern and a potential need to raise capital. Positive EBITDA helps, but it has not yet stopped cash from declining.

The market had largely priced in disappointment before the report. Shares fell 39.6% from the $7.35 open after the August report to $4.44 just before this release. The stock now sits 31.6% below its 200-day moving average and only 4.5% above a 52-week low of $4.25 set on November 5. It is also roughly 45% below the inter-earnings high of $8.15 reached in early September. Investor sentiment slipped from marginally positive to marginally negative, but the move was tiny and leaves sentiment essentially neutral. Most Earnings Whispers trend readings, including price and AVWAP, remain negative, though momentum has turned positive.

The bottom line is that Journey Medical is becoming a more profitable company on a slower growth path, and this quarter exposed that gap. Margins, Adjusted EBITDA, prescriber breadth and pricing all improved, and the 2027 formulary win is a real catalyst. However, the revenue miss, sharp deceleration, soft October scripts, deferred guidance and shrinking cash give bears legitimate ammunition. With the stock already near its lows, the next test is whether Q4 prescriptions recover from the copay disruption and whether the January payer win shows up in volume. Until then, the improved earnings profile is unlikely to outweigh the growth story.